Opioid-Related Disorder
Wearable Device Cleared for Use During Opioid Detoxification

Wearable Device Cleared for Use During Opioid Detoxification

Electrical pulses are sent through small needles that are inserted in the ear to combat the early stages of detoxification, leading to stabilization.

FDA Warns Websites Marketing Unapproved Opioids

FDA Warns Websites Marketing Unapproved Opioids

Nine online networks, operating 53 websites, have been warned that they must stop illegally marketing potentially dangerous versions of opioid medications.

Association Between Industry Payments and Opioid Prescribing

Association Between Industry Payments and Opioid Prescribing

Non-research industry payments to physicians may be associated with increases in opioid prescribing rates.

FDA Issues Warning to Companies Selling Kratom-Containing Products

FDA Issues Warning to Companies Selling Kratom-Containing Products

The US Food and Drug Administration has issued warnings to 3 companies selling kratom-containing products with unsubstantiated claims regarding their effectiveness in conditions that include opioid withdrawal and addiction and chronic pain.

Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy

Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy

While many treatments for substance use disorder are not evidence based, several evidence-based approaches have shown effectiveness in court-mandated treatment settings.

HIV Viral Suppression Rates in Psychiatric Inpatients With Comorbid Substance Use Disorders

HIV Viral Suppression Rates in Psychiatric Inpatients With Comorbid Substance Use Disorders

A substantial proportion of these individuals diagnosed with HIV, psychiatric disorders, and substance use disorders are out of care and urgently require intervention.

Long-acting buprenorphine depot injections may be efficacious in treatment of opioid use disorder

Weekly or monthly buprenorphine depot injections were non-inferior to daily sublingual buprenorphine/naloxone in maintaining no evidence of illicit opioid use at 24 weeks in outpatients with opioid use disorder.

Unit-dose packaging of buprenorphine-naloxone associated with reduced pediatric unintentional exposures

Pediatric unintentional opioid exposures decreased by more than 75% following the introduction of child-resistant unit-dose packaging.

First Nonopioid Drug Approved for Managing Opioid Withdrawal Symptoms

First Nonopioid Drug Approved for Managing Opioid Withdrawal Symptoms

Lucemyra, a selective alpha 2-adrenergic receptor agonist, works by reducing the release of norepinephrine and decreasing sympathetic tone.

Opioid-Related Payments Linked to Increase in Opioid Rx

Opioid-Related Payments Linked to Increase in Opioid Rx

Receipt of opioid-related payments from industry in 2014 was associated with increased opioid prescribing in 2015.

Sign Up for Free e-newsletters